Global Search | Novartis

Hide Filters

Showing 2714 results

Press Release / Jul 20, 2021

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
Press Release / Aug 30, 2021

Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD

Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio® (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with…
Press Release / Aug 30, 2021

Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO

New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety…
Press Release / Aug 24, 2021

Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma

Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12…
Press Release / Aug 17, 2021

Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis

China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
Press Release / Aug 17, 2021

Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks

Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
Press Release / Sep 29, 2021

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients

Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
Press Release / Sep 21, 2021

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss

Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
Press Release / Sep 21, 2021

Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision

Cette acquisition souligne l’engagement de Novartis à utiliser des thérapies basées sur l’optogénétique pour redonner la vue aux patients atteints de cécité avancéeNovartis acquiert un programme…
Press Release / Sep 21, 2021

Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können

Mit der Übernahme unterstreicht Novartis ihre Absicht, das Sehvermögen von Patientinnen und Patienten mit einem fortgeschrittenen Sehverlust mittels Optogenetik wiederherzustellenNovartis sichert…